<code id='561B2FE752'></code><style id='561B2FE752'></style>
    • <acronym id='561B2FE752'></acronym>
      <center id='561B2FE752'><center id='561B2FE752'><tfoot id='561B2FE752'></tfoot></center><abbr id='561B2FE752'><dir id='561B2FE752'><tfoot id='561B2FE752'></tfoot><noframes id='561B2FE752'>

    • <optgroup id='561B2FE752'><strike id='561B2FE752'><sup id='561B2FE752'></sup></strike><code id='561B2FE752'></code></optgroup>
        1. <b id='561B2FE752'><label id='561B2FE752'><select id='561B2FE752'><dt id='561B2FE752'><span id='561B2FE752'></span></dt></select></label></b><u id='561B2FE752'></u>
          <i id='561B2FE752'><strike id='561B2FE752'><tt id='561B2FE752'><pre id='561B2FE752'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:17381
          Calling Bullshit course University of Washington
          Screenshot via callingbullshit.org

          Tired of alternative facts, fake news, and breathless hyperbole, two professors at the University of Washington are trying to strike a blow for science.

          Their weapon? A new course: “Calling Bullshit In the Age of Big Data.”

          advertisement

          The class website and colorful syllabus went online last month and almost instantly went viral.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Lessons Learned: This is why you network to find that industry job you want
          Lessons Learned: This is why you network to find that industry job you want

          MollyFergusonforSTATLessonsLearnedisSTATPlus’weeklycolumnoncareersinbiomedicine.Ifyou’rethinkingofju

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Study: Why relieving medical debt did not improve financial outcomes

          AdobePhilanthropistsandfoundationsliketheoneIworkfortakealotofcalculatedrisks.Weinvestinresearch,adv